PMID- 32277652
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20220218
IS  - 2241-6293 (Electronic)
IS  - 1107-0625 (Linking)
VI  - 25
IP  - 1
DP  - 2020 Jan-Feb
TI  - Kutkoside-an iridoid glycoside, exerts anti-proliferative effects in 
      drug-resistant human oral carcinoma cells by targeting PI3K/AKT signalling 
      pathway, inducing apoptosis and suppressing cell migration and invasion.
PG  - 338-343
AB  - PURPOSE: The main purpose of the current research work was to investigate the 
      anticancer potential of Kutkoside -a naturally occurring iridoid glycoside, 
      against drug-resistant human oral carcinoma cells along with evaluating its 
      effects on PI3K/AKT signalling pathway, cellular apoptosis, cell migration and 
      cell invasion. METHODS: Cell viability was assessed by using MTT colorimetric 
      assay, while effects on cellular apoptosis were evaluated by acridine orange 
      (AO)/ethidium bromide (EB) as well as by using flow cytometry employing annexin 
      V-FITC. Effects on cell migration and cell invasion were evaluated by in vitro 
      wound healing assay and transwell Matrigel assay. Effects on PI3K/AKT signalling 
      pathway were evaluated by western blot method. RESULTS: Kutkoside led to 
      significant and dose-dependent inhibition of HSC-2 human oral cancer cells using 
      doses of 0, 1.25, 2.5, 5, 10, 20, 40, 80 and 160 muM. Fluorescence microscopy 
      revealed that on increasing the dose of kutkoside, the number of both apoptotic 
      and necrotic cells increased, showing that Kutkoside induces apoptotic cell death 
      in HSC-2 oral cancer cell line in dose-dependent manner. Flow cytometry indicated 
      that the percentage of apoptotic cells at different dose exposures of Kutkoside, 
      namely 0, 8, 16 and 32 muM was 4.9%, 12.18%, 22.18% and 34.10%, respectively. 
      Kutkoside treatment also led to cell migration inhibition and cell invasion 
      inhibition. This molecule upregulated the expression of AKT and PI3K, 
      simultaneously downregulating the expressions of p-AKT and p-PI3K in a 
      dose-dependent manner. CONCLUSION: Kutkoside shows potential anticancer and 
      pro-apoptotic effects in HSC-2 oral carcinoma cells and as such may be developed 
      as a possible anticancer agent provided further studies are performed.
FAU - Hou, Jun-Chi
AU  - Hou JC
AD  - Department of Stomatology, Jining No.1 People's Hospital, Jining 272000 , 
      Shandong, China.
FAU - Xu, Xiao Nan
AU  - Xu XN
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Cinnamates)
RN  - 0 (Glucosides)
RN  - 0 (kutkoside)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
RIN - JBUON 2021 November-December; 26(6): 2714
ECI - J BUON. 2021 May-Jun;26(3):1179. PMID: 34268996
MH  - Apoptosis
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cinnamates/pharmacology/*therapeutic use
MH  - Glucosides/pharmacology/*therapeutic use
MH  - Humans
MH  - Mouth Neoplasms/*drug therapy/pathology
MH  - Neoplasm Invasiveness
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Signal Transduction
EDAT- 2020/04/12 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/04/12 06:00 [entrez]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PST - ppublish
SO  - J BUON. 2020 Jan-Feb;25(1):338-343.